Select Region or Location
Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • Other Americas
Europe
  • Austria
  • Belgium
  • Bulgaria
  • Croatia/Hrvatska
  • Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovak Republic
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
  • Other Europe
Asia Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Korea, Republic of
  • Malaysia
  • New Zealand
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Other Asia Pacific
Africa And Middle East
  • Egypt
  • Israel
  • Other Africa And Middle East
USD
Home Cart Sign in  
Chemical Structure| 108409-83-2 Chemical Structure| 108409-83-2

Structure of FH535
CAS No.: 108409-83-2

Chemical Structure| 108409-83-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

FH535 is an inhibitor of Wnt/β-catenin and PPAR with antitumor activities.

4.5 *For Research Use Only! Not for Human Use. We Do Not Sell to Patients.

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]}{[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}
    {[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of FH535

CAS No. :108409-83-2
Formula : C13H10Cl2N2O4S
M.W : 361.20
SMILES Code : O=S(C1=CC(Cl)=CC=C1Cl)(NC2=CC=C([N+]([O-])=O)C=C2C)=O
English Name :2,5-Dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide
MDL No. :MFCD01212888
InChI Key :AXNUEXXEQGQWPA-UHFFFAOYSA-N
Pubchem ID :3463933

Safety of FH535

Isoform Comparison

Biological Activity

Target
  • PPARγ

In Vitro:

Cell Line
Concentration Treated Time Description References
Caco2 cells 20 µM 2 hours To verify the protective effect of BBR on TNF-α induced TJ damage in Caco2 cells Int J Biol Sci. 2022 Jan 16;18(4):1381-1397.
KYSE-150R cells 20 µM 24 hours FH535 reduced the expression of nuclear β-catenin, reversed EMT phenotypes, and increased the radiosensitivity of KYSE-150R cells. J Transl Med. 2015 Mar 31;13:104.
ARPE-19 cells 0.5 µM 48 hours To assess the impact of FH535 on the activation of EMT; FH535 treatment significantly attenuated the increase of EMT-related markers in TGFβ1-treated ARPE-19 cells. J Neuroinflammation. 2024 Mar 26;21(1):75.
Transformed human hepatocytes (THH) 5 µM 48 hours The combination of AZD5363 and FH535 treatment displays a much greater (~80%) cell death. Cell Death Dis. 2020 Jul 17;11(7):540.
HTR-8/SVneo cells 30 mM 72 hours To investigate the effect of FH535 on glucose uptake and apoptosis in HTR-8/SVneo cells under high glucose conditions. The results showed that FH535 treatment reversed the glucose uptake dysfunction and apoptosis induced by high glucose. Biol Res. 2023 Aug 22;56(1):48.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Laser-induced CNV model Intravitreal injection 0.5 μmol/L Single treatment To evaluate the effect of FH535 on subretinal fibrosis; the area of transformed RPE was reduced by 52.57%. J Neuroinflammation. 2024 Mar 26;21(1):75.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.77mL

0.55mL

0.28mL

13.84mL

2.77mL

1.38mL

27.69mL

5.54mL

2.77mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories